Atorvastatin added to interferon beta for relapsing multiple sclerosis: A randomized controlled trial

Journal of Neurology

Volumn 259, Issue 11, 2012, Pages 2401-2413

  Kamm, Christian Philipp ^a   El Koussy, Marwan ^b   Humpert, Sebastian ^a   Findling, Oliver ^a   Von Bredow, Ferdinand ^b   Burren, Yuliya ^b   Schwegler, Guido ^c   Schött, Dagmar ^d   Donati, Filippo ^e   Müller, Martin ^f   Goebels, Norbert ^g   Müller, Felix ^h   Slotboom, Johannes ^b   Tettenborn, Barbara ^d   Kappos, Ludwig ⁱ   Naegelin, Yvonne ⁱ   Mattle, Heinrich Paul ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e Cantonal Hospital Lucerne ^*  (Switzerland)

^f LUZERNER KANTONSSPITAL   (Switzerland)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h Kantonsspital Muensterlingen   (Switzerland)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Atorvastatin; Interferon beta; Multiple sclerosis; Randomized clinical trial

Indexed keywords

ATORVASTATIN; GADOLINIUM; INTERFERON BETA SERINE; LIVER ENZYME; NEUTRALIZING ANTIBODY;

ADD ON THERAPY; ARTICLE; BRAIN SIZE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAY MATTER; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; TREATMENT OUTCOME; WHITE MATTER;

ADOLESCENT; ADULT; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; PYRROLES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84868195949     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6513-7     Document Type: Article

References (37)

1. Kobashigawa JA, Katznelson S, Laks H et al (1995) Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621-627
2. Lassmann H, Brück W, Lucchinetti CF (2007) The immunopa-thology of multiple sclerosis. An overview. Brain Pathol 17:210-218
3. Stanislaus R, Pahan K, Singh AK, Singh I (1999) Amelioration of experimental allergic encephalomyelitis in Lewis rats by lova-statin. Neurosci Lett 269:71-74 (Pubitemid 29335415)
4. Stanislaus R, Singh AK, Singh I (2001) Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 66:155-162 (Pubitemid 32912284)
5. Youssef S, Stuve O, Patarroyo JC et al (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78-84 (Pubitemid 35291443)
6. Markovic-Plese S, Singh AK, Singh I (2008) Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair. Future Neurol 3:153-167 (Pubitemid 351395069)
7. Klopfleisch S, Merkler D, Schmitz M et al (2008) Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J Neurosci 28:13609-13614
8. Miron VE, Zehntner SP, Kuhlmann T et al (2009) Statin therapy inhibits remyelination in the central nervous system. Am J Pathol 174:1880-1890
9. Vollmer T, Key L, Durkalski V et al (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607-1608 (Pubitemid 38625664)
10. Paul F, Waiczies S, Wuerfel J et al (2008) Oral high-dose ator-vastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE 3:e1928
11. Togha M, Karvigh SA, Nabavi M et al (2010) Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler 16:848-854
12. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT (2008) Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71:1390-1395
13. Rudick RA, Pace A, Rani MR et al (2009) Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 72:1989-1993
14. Lanzillo R, Orefice G, Quarantelli M et al (2010) Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler 16:450-454
15. Sorensen PS, Lycke J, Erälinna JP et al (2011) Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol 10:691-701
16. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
17. Kamm CP, Mattle HP, SWABIMS Study Group (2009) SWiss atorvastatin and interferon beta-1b trial in multiple sclerosis (SWABIMS)-rationale, design and methodology. Trials 14:110-115
18. Beller EM, Gebski V, Keech AC (2002) Randomisation in clinical trials. Med J Aust 177:565-567 (Pubitemid 35422821)
19. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452 (Pubitemid 14237132)
20. Fischer JS, Rudick RA, Cutter GR, Reingold SC (1999) The multiple sclerosis functional composite measure (MSFC). An integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 5:244-250 (Pubitemid 29405620)
21. Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6:1399-1402 (Pubitemid 32001026)
22. Arca M (2007) Atorvastatin: a safety and tolerability profile. Drugs 67(1):63-69
23. Bernini F, Poli A, Paoletti R (2001) Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovasc Drugs Ther 15:211-218 (Pubitemid 33010603)
24. LaRosa JC, Grundy SM, Waters DD et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435 (Pubitemid 40471450)
25. ICH harmonised tripartite guideline-guideline for good clinical practice: E6(R1). Geneva: International Conference on Harmo-nisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, June 10, 1996. Accessed January 8, 2010, at http://www.ich.org/LOB/media/MEDIA482.pdf
26. Declaration of Helsinki: ethical principles for medical research involving human subjects. Ferney-Voltaire, France: World Medical Association, 2006. Accessed Jan 8, 2010, at http://www.wma.net/en/30publications/10policies/ b3/index.html
27. Ashburner J, Friston KJ (2005) Unified segmentation. Neuroim-age 26:839-851 (Pubitemid 40825026)
28. Lee H, Prohovnik I (2008) Cross-validation of brain segmentation by SPM5 and SIENAX. Psychiatry Res 164:172-177
29. Slotboom J, Schaer R, Ozdoba C et al (2008) A novel method for analyzing DSCE-images with an application to tumor grading. Invest Radiol 43:843-853
30. WHO Expert Committee on Biological Standardization (1985) Thirty-fifth report. World Health Organ Tech Rep Ser 725:1-140
31. Bertolotto A, Malucchi S, Sala A et al (2002) Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73:148-153
32. Paty DW, Li DK, The UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:662-667 (Pubitemid 23121952)
33. Neuhaus O, Strasser-Fuchs S, Fazekas F et al (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59:990-997
34. Dhawan N, Reder AT (2007) Statins block interferon signaling in human immune cells: potential loss of the therapeutic effect of IFN-B in multiple sclerosis. Neurology 68(suppl 1):A364
35. Kieseier BC, Archelos JJ, Hartung HP (2004) Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol 61:929-932 (Pubitemid 38747335)
36. Marrie RA, Rudick R, Horwitz R et al (2010) Vascular comor-bidity is associated with more rapid disability progression in multiple sclerosis. Neurology 74:1041-1047
37. Marrie RA, Horwitz R, Cutter G et al (2009) Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 72:117-124